Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

NF-κB/STAT3/PI3K signaling crosstalk in iMyc B lymphoma

Authors: Seong-Su Han, Hwakyung Yun, Dong-Ju Son, Van S. Tompkins, Liangping Peng, Seung-Tae Chung, Joong-Su Kim, Eun-Sung Park, Siegfried Janz

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Myc is a well known driver of lymphomagenesis, and Myc-activating chromosomal translocation is the recognized hallmark of Burkitt lymphoma, an aggressive form of non-Hodgkin's lymphoma. We developed a model that mimics this translocation event by inserting a mouse Myc cDNA gene into the immunoglobulin heavy chain locus, just upstream of the intronic Eμ enhancer. These mice, designated iMyc, readily develop B-cell lymphoma. To study the mechanism of Myc-induced lymphoma, we analyzed signaling pathways in lymphoblastic B-cell lymphomas (LBLs) from iMyc mice, and an LBL-derived cell line, iMyc-1.

Results

Nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) were constitutively activated in iMyc mice, not only in LBLs but also in the splenic B-lymphocytes of young animals months before tumors developed. Moreover, inhibition of either transcription factor in iMyc-1 cells suppressed growth and caused apoptosis, and the abrogation of NF-κB activity reduced DNA binding by both STAT3 and Myc, as well as Myc expression. Inhibition of STAT3 signaling eliminated the activity of both NF-κB and Myc, and resulted in a corresponding decrease in the level of Myc. Thus, in iMyc-1 cells NF-κB and STAT3 are co-dependent and can both regulate Myc. Consistent with this, NF-κB and phosphorylated STAT3 were physically associated with one another. In addition, LBLs and iMyc-1 cells also showed constitutive AKT phosphorylation. Blocking AKT activation by inhibiting PI3K reduced iMyc-1 cell proliferation and caused apoptosis, via downregulation of NF-κB and STAT3 activity and a reduction of Myc levels. Co-treatment with NF-κB, STAT3 or/and PI3K inhibitors led to additive inhibition of iMyc-1 cell proliferation, suggesting that these signaling pathways converge.

Conclusions

Our findings support the notion that constitutive activation of NF-κB and STAT3 depends on upstream signaling through PI3K, and that this activation is important for cell survival and proliferation, as well as for maintaining the level of Myc. Together, these data implicate crosstalk among NF-κB, STAT3 and PI3K in the development of iMyc B-cell lymphomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dörken B: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997, 100: 2961-2969. 10.1172/JCI119849PubMedCentralCrossRefPubMed Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dörken B: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997, 100: 2961-2969. 10.1172/JCI119849PubMedCentralCrossRefPubMed
2.
go back to reference Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001, 194: 1861-1874. 10.1084/jem.194.12.1861PubMedCentralCrossRefPubMed Davis RE, Brown KD, Siebenlist U, Staudt LM: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001, 194: 1861-1874. 10.1084/jem.194.12.1861PubMedCentralCrossRefPubMed
3.
go back to reference Bassères DS, Baldwin AS: Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene. 2006, 25: 6817-6830. 10.1038/sj.onc.1209942CrossRefPubMed Bassères DS, Baldwin AS: Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene. 2006, 25: 6817-6830. 10.1038/sj.onc.1209942CrossRefPubMed
4.
go back to reference Squarize CH, M Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS: Molecular Crosstalk between the NF-κB and STAT3 Signaling Pathways in Head and Neck Squamous Cell Carcinoma. Neoplasia. 2006, 8: 733-746. 10.1593/neo.06274PubMedCentralCrossRefPubMed Squarize CH, M Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS: Molecular Crosstalk between the NF-κB and STAT3 Signaling Pathways in Head and Neck Squamous Cell Carcinoma. Neoplasia. 2006, 8: 733-746. 10.1593/neo.06274PubMedCentralCrossRefPubMed
5.
go back to reference Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Sierra J, Prat J: Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology. 2008, 53: 441-449. 10.1111/j.1365-2559.2008.03139.xCrossRefPubMed Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Sierra J, Prat J: Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology. 2008, 53: 441-449. 10.1111/j.1365-2559.2008.03139.xCrossRefPubMed
6.
go back to reference Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2: 725-734. 10.1038/nri910CrossRefPubMed Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2: 725-734. 10.1038/nri910CrossRefPubMed
7.
go back to reference Baeuerle PA, Baltimore D: NF-κB. ten years after. Cell. 1996, 87: 13-20. 10.1016/S0092-8674(00)81318-5CrossRefPubMed Baeuerle PA, Baltimore D: NF-κB. ten years after. Cell. 1996, 87: 13-20. 10.1016/S0092-8674(00)81318-5CrossRefPubMed
8.
go back to reference Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000, 18: 621-663. 10.1146/annurev.immunol.18.1.621CrossRefPubMed Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000, 18: 621-663. 10.1146/annurev.immunol.18.1.621CrossRefPubMed
9.
go back to reference Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703CrossRefPubMed Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703CrossRefPubMed
10.
go back to reference Siebenlist U, Brown K, Claudio E: Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol. 2005, 5: 435-445. 10.1038/nri1629CrossRefPubMed Siebenlist U, Brown K, Claudio E: Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol. 2005, 5: 435-445. 10.1038/nri1629CrossRefPubMed
11.
go back to reference Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197: 157-168. 10.1002/jcp.10364CrossRefPubMed Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197: 157-168. 10.1002/jcp.10364CrossRefPubMed
12.
go back to reference Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19: 2474-2488. 10.1038/sj.onc.1203527CrossRefPubMed Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19: 2474-2488. 10.1038/sj.onc.1203527CrossRefPubMed
13.
go back to reference Joo A, Aburatani H, Morii E, Iba H, Yoshimura A: STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression. Oncogene. 2004, 23: 726-734. 10.1038/sj.onc.1207174CrossRefPubMed Joo A, Aburatani H, Morii E, Iba H, Yoshimura A: STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression. Oncogene. 2004, 23: 726-734. 10.1038/sj.onc.1207174CrossRefPubMed
14.
go back to reference Akira S, Nishi Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994, 77: 63-71. 10.1016/0092-8674(94)90235-6CrossRefPubMed Akira S, Nishi Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994, 77: 63-71. 10.1016/0092-8674(94)90235-6CrossRefPubMed
16.
go back to reference Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000, 19: 2548-2556. 10.1038/sj.onc.1203551CrossRefPubMed Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000, 19: 2548-2556. 10.1038/sj.onc.1203551CrossRefPubMed
17.
go back to reference O'Shea JJ: Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity. 1997, 7: 1-11. 10.1016/S1074-7613(00)80505-1CrossRefPubMed O'Shea JJ: Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity. 1997, 7: 1-11. 10.1016/S1074-7613(00)80505-1CrossRefPubMed
18.
go back to reference Decker T, Kovarik P: Serine phosphorylation of STATs. Oncogene. 2000, 19: 2628-2637. 10.1038/sj.onc.1203481CrossRefPubMed Decker T, Kovarik P: Serine phosphorylation of STATs. Oncogene. 2000, 19: 2628-2637. 10.1038/sj.onc.1203481CrossRefPubMed
19.
go back to reference Wen Z, Zhong Z, Darnell JE: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995, 82: 241-250. 10.1016/0092-8674(95)90311-9CrossRefPubMed Wen Z, Zhong Z, Darnell JE: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995, 82: 241-250. 10.1016/0092-8674(95)90311-9CrossRefPubMed
20.
go back to reference Schuringa JJ, Schepers H, Vellenga E, Kruijer W: Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL6 stimulation. FEBS Lett. 2001, 495: 71-76. 10.1016/S0014-5793(01)02354-7CrossRefPubMed Schuringa JJ, Schepers H, Vellenga E, Kruijer W: Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL6 stimulation. FEBS Lett. 2001, 495: 71-76. 10.1016/S0014-5793(01)02354-7CrossRefPubMed
21.
go back to reference Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296: 1655-1657. 10.1126/science.296.5573.1655CrossRefPubMed Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296: 1655-1657. 10.1126/science.296.5573.1655CrossRefPubMed
22.
go back to reference Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003, 17: 590-603. 10.1038/sj.leu.2402824CrossRefPubMed Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003, 17: 590-603. 10.1038/sj.leu.2402824CrossRefPubMed
23.
go back to reference Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005, 205: 498-506. 10.1002/path.1725CrossRefPubMed Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005, 205: 498-506. 10.1002/path.1725CrossRefPubMed
24.
go back to reference Fillmore GC, Wang Q, Carey MJ, Kim CH, Elenitoba-Johnson KS, Lim MS: Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma. 2005, 46: 1765-1773. 10.1080/10428190500159944CrossRefPubMed Fillmore GC, Wang Q, Carey MJ, Kim CH, Elenitoba-Johnson KS, Lim MS: Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma. 2005, 46: 1765-1773. 10.1080/10428190500159944CrossRefPubMed
25.
go back to reference Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006, 108: 1668-1676. 10.1182/blood-2006-04-015586PubMedCentralCrossRefPubMed Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006, 108: 1668-1676. 10.1182/blood-2006-04-015586PubMedCentralCrossRefPubMed
26.
go back to reference Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC: The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005, 8: 108-18. 10.1038/sj.pcan.4500776CrossRefPubMed Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC: The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005, 8: 108-18. 10.1038/sj.pcan.4500776CrossRefPubMed
27.
go back to reference Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 2000, 100: 387-390. 10.1016/S0092-8674(00)80674-1CrossRefPubMed Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 2000, 100: 387-390. 10.1016/S0092-8674(00)80674-1CrossRefPubMed
28.
go back to reference Giri D, Ittmann M: Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol. 1999, 30: 419-424. 10.1016/S0046-8177(99)90117-XCrossRefPubMed Giri D, Ittmann M: Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol. 1999, 30: 419-424. 10.1016/S0046-8177(99)90117-XCrossRefPubMed
29.
go back to reference Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998, 95: 29-39. 10.1016/S0092-8674(00)81780-8CrossRefPubMed Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998, 95: 29-39. 10.1016/S0092-8674(00)81780-8CrossRefPubMed
30.
go back to reference Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60: 1541-1545.PubMed Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60: 1541-1545.PubMed
31.
go back to reference Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Chung ST, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005, 65: 1306-1315. 10.1158/0008-5472.CAN-04-0268CrossRefPubMed Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Chung ST, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005, 65: 1306-1315. 10.1158/0008-5472.CAN-04-0268CrossRefPubMed
32.
go back to reference Han SS, Shaffer AL, Peng L, Chung ST, Lim JH, Maeng S, Kim JS, McNeil N, Ried T, Staudt LM, Janz SL: Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. Mol Cancer. 2005, 9: 4-40. Han SS, Shaffer AL, Peng L, Chung ST, Lim JH, Maeng S, Kim JS, McNeil N, Ried T, Staudt LM, Janz SL: Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. Mol Cancer. 2005, 9: 4-40.
33.
go back to reference Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE: Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med. 1995, 181: 1169-1177. 10.1084/jem.181.3.1169CrossRefPubMed Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE: Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med. 1995, 181: 1169-1177. 10.1084/jem.181.3.1169CrossRefPubMed
34.
go back to reference Wu M, Arsura M, Bellas RE, FitzGerald MJ, Lee H, Schauer SL, Sherr DH, Sonenshein GE: Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol. 1995, 16: 5015-5025.CrossRef Wu M, Arsura M, Bellas RE, FitzGerald MJ, Lee H, Schauer SL, Sherr DH, Sonenshein GE: Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol. 1995, 16: 5015-5025.CrossRef
35.
go back to reference Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996, 15: 4682-4690.PubMedCentralPubMed Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996, 15: 4682-4690.PubMedCentralPubMed
36.
go back to reference Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999, 93: 152-161. 10.1006/clim.1999.4769CrossRefPubMed Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999, 93: 152-161. 10.1006/clim.1999.4769CrossRefPubMed
37.
go back to reference Han SS, Chung ST, Robertson DA, Chelvarajan RL, Bondada S: CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1. Int Immunol. 1999, 11: 871-879. 10.1093/intimm/11.6.871CrossRefPubMed Han SS, Chung ST, Robertson DA, Chelvarajan RL, Bondada S: CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1. Int Immunol. 1999, 11: 871-879. 10.1093/intimm/11.6.871CrossRefPubMed
38.
go back to reference Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI: Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008, 14: 447-57. 10.1016/j.ccr.2008.10.018CrossRefPubMed Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI: Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008, 14: 447-57. 10.1016/j.ccr.2008.10.018CrossRefPubMed
39.
go back to reference Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999, 189: 63-73. 10.1084/jem.189.1.63PubMedCentralCrossRefPubMed Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999, 189: 63-73. 10.1084/jem.189.1.63PubMedCentralCrossRefPubMed
40.
go back to reference Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008, 111: 1515-1523. 10.1182/blood-2007-04-087734PubMedCentralCrossRefPubMed Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008, 111: 1515-1523. 10.1182/blood-2007-04-087734PubMedCentralCrossRefPubMed
41.
go back to reference Duyao MP, Buckler AJ, Sonenshein GE: Interaction of an NF-kB-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci USA. 1990, 87: 4727-4731. 10.1073/pnas.87.12.4727PubMedCentralCrossRefPubMed Duyao MP, Buckler AJ, Sonenshein GE: Interaction of an NF-kB-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci USA. 1990, 87: 4727-4731. 10.1073/pnas.87.12.4727PubMedCentralCrossRefPubMed
42.
go back to reference Yu Z, Zhang W, Kone BC: Signal transducers and activators of transcription 3 STAT3 inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J. 2002, 367: 97-105. 10.1042/BJ20020588PubMedCentralCrossRefPubMed Yu Z, Zhang W, Kone BC: Signal transducers and activators of transcription 3 STAT3 inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J. 2002, 367: 97-105. 10.1042/BJ20020588PubMedCentralCrossRefPubMed
43.
go back to reference Yu Z, Kone BC: The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and iuducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol. 2004, 15: 585-591. 10.1097/01.ASN.0000114556.19556.F9CrossRefPubMed Yu Z, Kone BC: The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and iuducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol. 2004, 15: 585-591. 10.1097/01.ASN.0000114556.19556.F9CrossRefPubMed
44.
go back to reference Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21: 1396-1408. 10.1101/gad.1553707PubMedCentralCrossRefPubMed Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21: 1396-1408. 10.1101/gad.1553707PubMedCentralCrossRefPubMed
45.
go back to reference Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA, Auron PE: Interleukin 1 activates STAT3/nuclear factor-κB crosstalk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem. 2004, 279: 1768-1776. 10.1074/jbc.M311498200CrossRefPubMed Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA, Auron PE: Interleukin 1 activates STAT3/nuclear factor-κB crosstalk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem. 2004, 279: 1768-1776. 10.1074/jbc.M311498200CrossRefPubMed
46.
go back to reference Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009, 15: 283-293. 10.1016/j.ccr.2009.02.015PubMedCentralCrossRefPubMed Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009, 15: 283-293. 10.1016/j.ccr.2009.02.015PubMedCentralCrossRefPubMed
47.
go back to reference Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005, 94: 29-86. 10.1016/S0065-230X(05)94002-5CrossRefPubMed Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005, 94: 29-86. 10.1016/S0065-230X(05)94002-5CrossRefPubMed
48.
go back to reference Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005, 7: 561-573. 10.1016/j.ccr.2005.05.014CrossRefPubMed Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005, 7: 561-573. 10.1016/j.ccr.2005.05.014CrossRefPubMed
49.
go back to reference Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008, 111: 3701-3713. 10.1182/blood-2007-09-111948PubMedCentralCrossRefPubMed Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008, 111: 3701-3713. 10.1182/blood-2007-09-111948PubMedCentralCrossRefPubMed
50.
go back to reference Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007, 109: 2293-2302. 10.1182/blood-2006-02-003988CrossRefPubMed Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007, 109: 2293-2302. 10.1182/blood-2006-02-003988CrossRefPubMed
51.
go back to reference Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N: EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007, 3: e166- 10.1371/journal.ppat.0030166PubMedCentralCrossRefPubMed Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N: EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007, 3: e166- 10.1371/journal.ppat.0030166PubMedCentralCrossRefPubMed
52.
go back to reference Ghosh AK, Kay NE, Secreto CR, Shanafelt TD: Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009, 15: 1250-1258. 10.1158/1078-0432.CCR-08-1511PubMedCentralCrossRefPubMed Ghosh AK, Kay NE, Secreto CR, Shanafelt TD: Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009, 15: 1250-1258. 10.1158/1078-0432.CCR-08-1511PubMedCentralCrossRefPubMed
53.
go back to reference Heckman CA, Mehew JW, Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002, 21: 3898-3908. 10.1038/sj.onc.1205483CrossRefPubMed Heckman CA, Mehew JW, Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002, 21: 3898-3908. 10.1038/sj.onc.1205483CrossRefPubMed
54.
go back to reference Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY, Boxter LM: Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res. 2003, 63: 6666-6673.PubMed Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY, Boxter LM: Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res. 2003, 63: 6666-6673.PubMed
55.
go back to reference Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002, 2: 920-932. 10.1038/nri953CrossRefPubMed Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002, 2: 920-932. 10.1038/nri953CrossRefPubMed
56.
go back to reference Zhou H, Du MQ, Dixit VM: Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell. 2005, 7: 425-431. 10.1016/j.ccr.2005.04.012CrossRefPubMed Zhou H, Du MQ, Dixit VM: Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell. 2005, 7: 425-431. 10.1016/j.ccr.2005.04.012CrossRefPubMed
57.
go back to reference Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 2001, 115: 279-286. 10.1046/j.1365-2141.2001.03102.xCrossRefPubMed Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 2001, 115: 279-286. 10.1046/j.1365-2141.2001.03102.xCrossRefPubMed
58.
go back to reference Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003, 171: 88-95.CrossRefPubMed Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003, 171: 88-95.CrossRefPubMed
59.
go back to reference Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006, 107: 4540-4548. 10.1182/blood-2005-10-4042PubMedCentralCrossRefPubMed Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006, 107: 4540-4548. 10.1182/blood-2005-10-4042PubMedCentralCrossRefPubMed
60.
go back to reference Keutgens A, Robert I, Viatour P, Chariot A: Deregulated NF-kappaB activity in haematological malignancies. Biochem Pharmacol. 2006, 72: 1069-1080. 10.1016/j.bcp.2006.06.011CrossRefPubMed Keutgens A, Robert I, Viatour P, Chariot A: Deregulated NF-kappaB activity in haematological malignancies. Biochem Pharmacol. 2006, 72: 1069-1080. 10.1016/j.bcp.2006.06.011CrossRefPubMed
61.
go back to reference Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020CrossRefPubMed Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020CrossRefPubMed
62.
go back to reference Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H: STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001, 98: 762-770. 10.1182/blood.V98.3.762CrossRefPubMed Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H: STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001, 98: 762-770. 10.1182/blood.V98.3.762CrossRefPubMed
63.
go back to reference Momose S, Tamaru J, Kishi H, Mikata I, Mori M, Toyozumi Y, Itoyama S: Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol. 2009, 40: 75-82. 10.1016/j.humpath.2008.06.009CrossRefPubMed Momose S, Tamaru J, Kishi H, Mikata I, Mori M, Toyozumi Y, Itoyama S: Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol. 2009, 40: 75-82. 10.1016/j.humpath.2008.06.009CrossRefPubMed
64.
go back to reference Agrawal A, Cha-Molstad H, Samols D, Kushner I: Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology. 2003, 108: 539-547. 10.1046/j.1365-2567.2003.01608.xPubMedCentralCrossRefPubMed Agrawal A, Cha-Molstad H, Samols D, Kushner I: Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology. 2003, 108: 539-547. 10.1046/j.1365-2567.2003.01608.xPubMedCentralCrossRefPubMed
65.
go back to reference Yuan ZL, Guan YJ, Chatterjee D, Chin YE: Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005, 307: 269-273. 10.1126/science.1105166CrossRefPubMed Yuan ZL, Guan YJ, Chatterjee D, Chin YE: Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005, 307: 269-273. 10.1126/science.1105166CrossRefPubMed
66.
go back to reference Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K: Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells. 2005, 10. 1051-1063. 10.1111/j.1365-2443.2005.00900.xCrossRefPubMed Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K: Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells. 2005, 10. 1051-1063. 10.1111/j.1365-2443.2005.00900.xCrossRefPubMed
67.
go back to reference Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985, 318: 533-538. 10.1038/318533a0CrossRefPubMed Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985, 318: 533-538. 10.1038/318533a0CrossRefPubMed
68.
go back to reference Grumont RJ, Strasser A, Gerondakis S: B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell. 2002, 10: 1283-1294. 10.1016/S1097-2765(02)00779-7CrossRefPubMed Grumont RJ, Strasser A, Gerondakis S: B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell. 2002, 10: 1283-1294. 10.1016/S1097-2765(02)00779-7CrossRefPubMed
69.
go back to reference Lee S, Choi EJ, Jin C, Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005, 97: 26-34. 10.1016/j.ygyno.2004.11.051CrossRefPubMed Lee S, Choi EJ, Jin C, Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005, 97: 26-34. 10.1016/j.ygyno.2004.11.051CrossRefPubMed
70.
go back to reference Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld MP: PTEN gene alterations in lymphoid neoplasms. Blood. 1998, 92: 3410-3415.PubMed Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld MP: PTEN gene alterations in lymphoid neoplasms. Blood. 1998, 92: 3410-3415.PubMed
71.
go back to reference Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004, 3: 1221-1224.CrossRefPubMed Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004, 3: 1221-1224.CrossRefPubMed
72.
go back to reference Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005, 90: 4688-4693. 10.1210/jc.2004-2281CrossRefPubMed Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005, 90: 4688-4693. 10.1210/jc.2004-2281CrossRefPubMed
73.
go back to reference Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006, 118: 1877-1883. 10.1002/ijc.21461CrossRefPubMed Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006, 118: 1877-1883. 10.1002/ijc.21461CrossRefPubMed
74.
go back to reference García JF, Camacho FI, Morente M, Fraga M, Montalbán C, Alvaro T, Bellas C, Castaño A, Díez A, Flores T, Martin C, Martinez MA, Mazorra F, Menárguez J, Mestre MJ, Mollejo M, Sáez AI, Sánchez L, Piris MA: Spanish Hodgkin Lymphoma Study Group. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003, 101: 681-689. 10.1182/blood-2002-04-1128CrossRefPubMed García JF, Camacho FI, Morente M, Fraga M, Montalbán C, Alvaro T, Bellas C, Castaño A, Díez A, Flores T, Martin C, Martinez MA, Mazorra F, Menárguez J, Mestre MJ, Mollejo M, Sáez AI, Sánchez L, Piris MA: Spanish Hodgkin Lymphoma Study Group. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003, 101: 681-689. 10.1182/blood-2002-04-1128CrossRefPubMed
75.
go back to reference Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S: Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008, 17: 159-65. 10.1097/PDM.0b013e31815d0588CrossRefPubMed Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S: Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008, 17: 159-65. 10.1097/PDM.0b013e31815d0588CrossRefPubMed
76.
go back to reference Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1038/43466CrossRefPubMed Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1038/43466CrossRefPubMed
77.
go back to reference Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999, 401: 86-90. 10.1038/43474CrossRefPubMed Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999, 401: 86-90. 10.1038/43474CrossRefPubMed
78.
go back to reference Fung MM, Rohwer F, McGuire KL: IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell Signal. 2003, 15: 625-636. 10.1016/S0898-6568(03)00003-2CrossRefPubMed Fung MM, Rohwer F, McGuire KL: IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell Signal. 2003, 15: 625-636. 10.1016/S0898-6568(03)00003-2CrossRefPubMed
79.
go back to reference Krasil'nikov M, Shatskaya V: Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J Steroid Biochem Mol Biol. 2002, 82: 369-376. 10.1016/S0960-0760(02)00223-6CrossRefPubMed Krasil'nikov M, Shatskaya V: Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J Steroid Biochem Mol Biol. 2002, 82: 369-376. 10.1016/S0960-0760(02)00223-6CrossRefPubMed
80.
go back to reference Chen LF, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001, 293: 1653-1657. 10.1126/science.1062374CrossRef Chen LF, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001, 293: 1653-1657. 10.1126/science.1062374CrossRef
81.
go back to reference Huang WC, Chen CC: Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 2005, 25: 6592-6602. 10.1128/MCB.25.15.6592-6602.2005PubMedCentralCrossRefPubMed Huang WC, Chen CC: Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 2005, 25: 6592-6602. 10.1128/MCB.25.15.6592-6602.2005PubMedCentralCrossRefPubMed
82.
go back to reference Ohbayashi N, Ikeda O, Taira N, Yamamoto Y, Muromoto R, Sekine Y, Sugiyama K, Honjoh T, Matsuda T: LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull. 2007, 30: 1860-4. 10.1248/bpb.30.1860CrossRefPubMed Ohbayashi N, Ikeda O, Taira N, Yamamoto Y, Muromoto R, Sekine Y, Sugiyama K, Honjoh T, Matsuda T: LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull. 2007, 30: 1860-4. 10.1248/bpb.30.1860CrossRefPubMed
83.
go back to reference Ray S, Boldogh I, Brasier AR: STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology. 2005, 129: 1616-1632. 10.1053/j.gastro.2005.07.055CrossRefPubMed Ray S, Boldogh I, Brasier AR: STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology. 2005, 129: 1616-1632. 10.1053/j.gastro.2005.07.055CrossRefPubMed
Metadata
Title
NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma
Authors
Seong-Su Han
Hwakyung Yun
Dong-Ju Son
Van S. Tompkins
Liangping Peng
Seung-Tae Chung
Joong-Su Kim
Eun-Sung Park
Siegfried Janz
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-97

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine